Clinical Trial Update: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS [Phase 3]

View source ↗

Summary

This entry reports an ongoing Phase 3 long-term study assessing the safety, tolerability, and effectiveness of ofatumumab in patients with relapsing multiple sc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING